‘We just need someone who’s not crazy’: How the White House decided on Erica Schwartz for CDC director
White House Chooses Erica Schwartz to Steer CDC Through Turbulent Times
A Search for Stability After Years of Upheaval
We just need someone who s not – Over twelve months, the United States Centers for Disease Control and Prevention has endured considerable turmoil. A devastating shooting incident, sudden shifts in leadership, and damage to its reputation as an internationally recognized public health institution have all contributed to the agency’s challenges. When the Trump administration began searching for a replacement director, one criterion emerged above all others. According to a White House representative speaking with CNN during the extended selection process, the administration simply needed “someone who’s not crazy.” This sentiment ultimately led to President Trump selecting Erica Schwartz, a retired Coast Guard officer and former deputy surgeon general, for the position in April.
On Wednesday, Schwartz will appear before the Senate Health, Education, Labor and Pensions Committee for her confirmation hearing. She will testify alongside Sean Kaufman, who has been nominated by the president to serve as Assistant Secretary of Preparedness and Response. Senior health officials and sources familiar with the selection process told CNN that Schwartz’s appointment was designed to restore stability to an agency experiencing nearly continuous disruption. This instability has severely damaged employee morale and undermined public confidence in the administration’s health priorities.
Testing Grounds for CDC Leadership
The necessity for competent CDC leadership has grown even more pressing in recent months. The public health organization has been managing several disease challenges simultaneously. It has provided assistance for an Ebola outbreak occurring in central Africa while also working to control a surge in parasitic diarrhea affecting numerous states across the country.
Schwartz represents a significant shift from previous candidates the administration considered, many of whom aligned with the “Make America Healthy Again” movement. She possesses an extensive history of managing vaccination initiatives and responding to public health emergencies on behalf of the federal government. This background stands in sharp contrast to Trump’s initial CDC selection, whose nomination was eventually withdrawn after it became apparent that his skepticism regarding vaccines would create obstacles to confirmation.
“She’s a good and well-qualified nominee, and would be in any administration. However, the issue is not her qualifications — it’s the environment that she’s being asked to work in,” said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security and spokesperson for the Infectious Diseases Society of America.
“If this is supposed to be some kind of pivot away from what’s been going on for the last year, it will all be window dressing if RFK Jr. is still in place.”
Political Implications and Reactions
Schwartz’s nomination has already received positive feedback from lawmakers on Capitol Hill, creating optimism within the White House that confirmation could happen swiftly. As the administration increases its attention on upcoming midterm elections, this appointment signals how considerably Trump’s team has attempted to constrain the Health and Human Services Department under Robert F. Kennedy Jr., which previously had considerable freedom to pursue controversial initiatives related to vaccines and other fundamental health policies.
Nevertheless, the decision has unsettled supporters of the Make America Healthy Again movement while failing to fully convince certain mainstream public health professionals. Dr. Amesh Adalja’s comments highlight concerns that the appointment may not represent genuine change if Kennedy remains in his position.
“The White House isn’t even trying to win the midterms at this point,” added Toby Rogers, a prominent vaccine critic, who declared on X that Schwartz’s appointment would be “a slap in the face to the medical freedom base that gave Trump the presidency in 2016 and 2024.”
A History of CDC Leadership Challenges
The White House has demonstrated eagerness to move the health department away from negative press coverage before midterm elections that could potentially cost Republicans control of Congress and impede President Trump’s legislative priorities. Vaccines have consistently been a contentious issue throughout this process.
Trump initially withdrew his first nominee, former congressman Dr. Dave Weldon, when it became evident that Weldon’s positions on vaccines would delay a confirmation vote. The CDC director who ultimately received confirmation, Dr. Susan Monarez, a scientist and experienced public health official, quickly found herself in conflict with Kennedy over vaccine policies and his attempts to remove certain senior CDC officials. Monarez was dismissed less than one month after beginning her tenure.
Following Monarez’s high-profile exit last August, several Trump administration officials debated whether pursuing another nominee for the agency was worthwhile. Kennedy appointed his then-deputy secretary, Jim O’Neill, as interim head and attempted to centralize decision-making authority among the department’s political leadership in Washington. However, senior White House and HHS officials eventually became dissatisfied with O’Neill, who seldom visited the CDC’s Atlanta headquarters and was viewed by political appointees as an inadequate public communicator.
The White House has not yet responded to requests for comment regarding Schwartz’s upcoming confirmation hearing.